These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 25465817)
1. Tirofiban induced anemia without thrombocytopenia. Ede H; Erkoç MF; Alüzüm H; Özdemir ZT; Erbay AR Int J Cardiol; 2015 Jan; 179():500-1. PubMed ID: 25465817 [No Abstract] [Full Text] [Related]
2. First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia). Sakellariou D; Pastromas S; Koulouris S; Manolis AS Tex Heart Inst J; 2009; 36(1):55-7. PubMed ID: 19436788 [TBL] [Abstract][Full Text] [Related]
3. Tirofiban-induced acute profound thrombocytopenia after primary angioplasty. Dursunoglu D; Taskoylu O; Gür S; Sari I Asian Cardiovasc Thorac Ann; 2013 Feb; 21(1):74-6. PubMed ID: 23430426 [TBL] [Abstract][Full Text] [Related]
4. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843 [TBL] [Abstract][Full Text] [Related]
5. Failure of enoxaparin during coronary stenting: a case report. Chisholm RJ; Cantor W Catheter Cardiovasc Interv; 2005 Nov; 66(3):343-5. PubMed ID: 16155892 [TBL] [Abstract][Full Text] [Related]
6. A misleading diagnosis in acute coronary syndrome: tirofiban-induced alveolar hemorrhage. Şarlı B; Uğurlu M; Tok A; Dondurmacı E; Sağ Ertürk F Turk Kardiyol Dern Ars; 2015 Dec; 43(8):753. PubMed ID: 26717345 [No Abstract] [Full Text] [Related]
7. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Eryonucu B; Tuncer M; Erkoc R Cardiovasc Drugs Ther; 2004 Nov; 18(6):503-5. PubMed ID: 15770438 [TBL] [Abstract][Full Text] [Related]
8. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW; JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052 [TBL] [Abstract][Full Text] [Related]
9. Safety of tirofiban therapy in very old patients with acute coronary syndrome or non-Q-wave myocardial infarction. Graf C; Nkoulou R; Trombert V; Perrenoud JJ J Am Geriatr Soc; 2005 Jan; 53(1):172-3. PubMed ID: 15667404 [No Abstract] [Full Text] [Related]
10. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Stepinska J; Banaszewski M; Konopka A; Szajewski T Thromb Haemost; 2002 Feb; 87(2):355-6. PubMed ID: 11858506 [No Abstract] [Full Text] [Related]
11. Role of tirofiban in treatment of stent thrombosis. Yalçin R; Taçoy G; Timurkaynak T; Cengel A Anadolu Kardiyol Derg; 2006 Jun; 6(2):180-1. PubMed ID: 16766287 [No Abstract] [Full Text] [Related]
13. [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists]. Feldmann C; Deutsch HJ Dtsch Med Wochenschr; 2005 Jan; 130(1-2):29-30. PubMed ID: 15619171 [No Abstract] [Full Text] [Related]
14. Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. Erdim R; Erciyes D; Görmez S; Karabay KO; Catakoğlu AB; Aytekin V; Demiroğlu C; Gülbaran M Anadolu Kardiyol Derg; 2010 Aug; 10(4):340-5. PubMed ID: 20693130 [TBL] [Abstract][Full Text] [Related]
15. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E; Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375 [TBL] [Abstract][Full Text] [Related]
16. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
17. Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia. Zhou X; Peng H; Yin Y; Huang H; Zeng J; Ouyang F Int J Cardiol; 2016 Mar; 206():93-4. PubMed ID: 26785031 [No Abstract] [Full Text] [Related]
18. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events. Dunkley S; Evans S; Gaudry L; Jepson N Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613 [TBL] [Abstract][Full Text] [Related]
19. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment. Mulot A; Moulin F; Fohlen-Walter A; Angioi M; Sghaier M; Carteaux JP; Lecompte T; de Maistre E Am J Hematol; 2004 Sep; 77(1):67-71. PubMed ID: 15307109 [TBL] [Abstract][Full Text] [Related]
20. Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Zhang Y; Gao C; Liu H; Wang X; Yang H; Li M; Wang X; Zhu Z; Hu D Clin Exp Pharmacol Physiol; 2013 Apr; 40(4):289-94. PubMed ID: 23551127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]